
Oculis to host R&D Day showcasing late-stage pipeline for dry eye and neuro-ophthalmology treatments
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...





